Tiffany Burke
Family Medicine · Durant, OKNPI 1417036104
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Indivior Inc. accounts for 64.2% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2024 at $6,112 and has fallen 98.4% since, to $100 in 2025. Among family medicine clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 476 payments — averaging $28.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$9K
- Johnson & Johnson$1K
- AbbVie$815
- Otsuka America Pharmaceutical, Inc.$691
- Neurocrine Biosciences, Inc.$485
- Teva Pharmaceuticals USA, Inc.$446
- plus $1K from 13 others
Across 4 payments — averaging $3187.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$13K
What the payments were for
- Speaking & faculty fees$5,23939%
- Travel & lodging$2,04015%
- Food & beverage$5,63642%
- Education$4153%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 75 | $8,552 |
| Johnson & Johnson | 88 | $1,077 |
| AbbVie | 83 | $815 |
| Otsuka America Pharmaceutical, Inc. | 69 | $691 |
| Neurocrine Biosciences, Inc. | 47 | $485 |
| Teva Pharmaceuticals USA, Inc. | 31 | $446 |
| Alkermes, Inc. | 25 | $400 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $389 |
| Lundbeck LLC | 21 | $206 |
| Sunovion Pharmaceuticals Inc. | 8 | $93 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Vanda Pharmaceuticals Inc. | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Sage Therapeutics, LLC | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Exact Sciences | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| GSK | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PERSERIS$7,340
How this compares
$13,330 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EnbrelEtanercept | 16 | $231,076 |
| Austedo XrDeutetrabenazine | 16 | $179,400 |
| Invega TrinzaPaliperidone Palmitate | 13 | $135,107 |
| IngrezzaValbenazine Tosylate | 16 | $127,777 |
| Abilify MaintenaAripiprazole | 29 | $85,590 |
| VraylarCariprazine Hcl | 52 | $74,505 |
| AristadaAripiprazole Lauroxil | 17 | $56,630 |
| PerserisRisperidone | 14 | $43,210 |
| RexultiBrexpiprazole | 16 | $25,391 |
| CaplytaLumateperone Tosylate | 12 | $18,748 |
| MounjaroTirzepatide | 17 | $18,744 |
| OzempicSemaglutide | 19 | $17,510 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $7,999 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,779 |
| Chlorzoxazone | 25 | $4,854 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $446 | $179,40016 claims |
| Johnson & JohnsonInvega Trinza | $1,077 | $135,10713 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $485 | $127,77716 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $691 | $110,98145 claims |
| AbbVieVraylar | $815 | $74,50552 claims |
| Alkermes, Inc.Aristada | $400 | $56,63017 claims |
| Indivior Inc.Perseris | $8,552 | $43,21014 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $389 | $18,74812 claims |
| Lilly USA, LLCMounjaro | $16 | $18,74417 claims |
| GSKTrelegy Ellipta | $13 | $7,99914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Durant
- Alexander FrankOklahoma City$3.1M
- Stanley ShadidEdmond$363K
- Geoffrey PlumleeTulsa$297K
- Curtis HarrisAda$125K
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
- Lisa ConneryNorman$105K
- Michael RobinsonElk City$84K
- Kimberly HuttonTulsa$76K
- James BeebeMuskogee$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.